BIIB Biogen Inc. Stock Quote

BIIB [NASD]

Healthcare | Drug Manufacturers - General | USA

Index	S&P 500	P/E	21.31	EPS (ttm)	19.06	Insider Own	0.10%	Shs Outstand	151.90M	Perf Week	2.60%
Market Cap	63.93B	Forward P/E	19.37	EPS next Y	20.97	Insider Trans	-6.10%	Shs Float	149.58M	Perf Month	44.17%
Income	3.01B	PEG	-	EPS next Q	4.57	Inst Own	86.90%	Short Float	2.10%	Perf Quarter	56.13%
Sales	12.60B	P/S	5.07	EPS this Y	-21.10%	Inst Trans	-1.22%	Short Ratio	1.82	Perf Half Y	67.15%
Book/sh	70.32	P/B	5.78	EPS next Y	12.54%	ROA	12.20%	Target Price	287.87	Perf Year	43.40%
Cash/sh	16.12	P/C	25.19	EPS next 5Y	-7.60%	ROE	27.70%	52W Range	223.25 - 468.55	Perf YTD	65.87%
Dividend	-	P/FCF	18.59	EPS past 5Y	10.10%	ROI	19.60%	52W High	-15.62%	Beta	0.40
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	4.50%	Gross Margin	85.50%	52W Low	77.09%	ATR	21.13
Employees	9100	Current Ratio	2.10	Sales Q/Q	-23.80%	Oper. Margin	29.40%	RSI (14)	74.99	Volatility	6.11% 6.42%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-66.70%	Profit Margin	23.90%	Rel Volume	0.98	Prev Close	406.14
Shortable	Yes	LT Debt/Eq	0.68	Earnings	Apr 22 BMO	Payout	0.00%	Avg Volume	1.73M	Price	395.35
Recom	2.80	SMA20	25.93%	SMA50	37.36%	SMA200	45.66%	Volume	1,645,679	Change	-2.66%

Jun-14-21

Reiterated

Truist

Buy

$458 → $647

Jun-11-21

Upgrade

Bernstein

Mkt Perform → Outperform

$500

Jun-10-21

Upgrade

UBS

Neutral → Buy

Jun-08-21

Upgrade

William Blair

Mkt Perform → Outperform

Jun-08-21

Upgrade

Robert W. Baird

Underperform → Neutral

$216 → $382

Jun-08-21

Upgrade

Citigroup

Sell → Neutral

$200 → $440

Jun-08-21

Upgrade

Atlantic Equities

Underweight → Neutral

$415

Jun-08-21

Reiterated

Stifel

Buy

$346 → $446

Jun-08-21

Reiterated

RBC Capital Mkts

Sector Perform

$259 → $400

Jun-08-21

Reiterated

Morgan Stanley

Overweight

$343 → $455

Jun-08-21

Reiterated

Jefferies

Buy

$450 → $500

Jun-08-21

Reiterated

H.C. Wainwright

Buy

$305 → $452

Jun-08-21

Reiterated

Barclays

Equal Weight

$265 → $395

Jun-07-21

Upgrade

Raymond James

Underperform → Mkt Perform

Jun-07-21

Upgrade

Cowen

Market Perform → Outperform

$225 → $450

Jun-07-21

Upgrade

BofA Securities

Underperform → Neutral

$235 → $400

Feb-05-21

Downgrade

DZ Bank

Buy → Hold

$264

Jan-29-21

Upgrade

Stifel

Hold → Buy

$258 → $358

Nov-10-20

Upgrade

DZ Bank

Hold → Buy

$265

Nov-09-20

Reiterated

H.C. Wainwright

Buy

$318 → $289

Jun-15-21 12:13PM	Biotechs Decline After Sage-Biogen Depression Drug Misses Mark Bloomberg
10:55AM	Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal Zacks
10:35AM	Following Its Major Regulatory Win, How Much Upside Does Biogen Have? Motley Fool
09:56AM	Sages Depression Drug Worked. The Stock Is Falling Anyway. Barrons.com
09:55AM	Where Will Biogen Be in 1 Year? Motley Fool
09:37AM	Where Do Hedge Funds Stand On Biogen Inc. (BIIB)? Insider Monkey
08:52AM	Biogen says experimental drug for rare retinal disease fails in late-stage clinical trial MarketWatch
07:16AM	Sage Therapeutics - Biogen's Zuranolone Tops Placebo In Reducing Depressive Symptoms Benzinga
07:12AM	These 3 Words From the FDA Ensure the Biogen Drama Is Far From Over Motley Fool
06:56AM	UPDATE 2-Sage's depression drug study results show improvement in symptoms Reuters
06:46AM	Sage, Biogen MDD treatment meets primary endpoint MarketWatch
06:30AM	Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder Business Wire
06:05AM	Yet Another Biogen's Retinal Disease Gene Therapy Fails In Late-Stage Study Benzinga
03:36AM	Sage Therapeutics Plunges After Depression Drug-Trial Results TheStreet.com
01:43AM	Biogen Falls Premarket As Eye Disease Treatment Fails Test Investing.com
Jun-14-21 04:06PM	Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia GlobeNewswire
12:57PM	Is Biogen (BIIB) A Good Stock To Buy? Insider Monkey
12:07PM	A Concerning Lowering of FDA Drug Approval Standards Barrons.com
11:10AM	Top-Performing Biotech ETFs of Last Week Zacks
03:00AM	Market Recap With Jim Cramer: Buy Chewy, Ford, Apple and Hold Biogen TheStreet.com
Jun-13-21 09:03AM	Biotech Rally Sparked by Alzheimers Drug Has Staying Power The Wall Street Journal
06:15AM	After a 50% Gain, Is It Too Late to Buy Biogen? Motley Fool
05:28AM	Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs Motley Fool
Jun-11-21 06:47PM	Biogens Alzheimers Drug Opens Up a New Market. These Stocks Could Benefit if More Approvals Come. Barrons.com
04:31PM	S&P 500 Hits Record High; Biogen Alzheimer's Drug, Tesla, Apple, RH, GameStop In Focus: Weekly Review Investor's Business Daily
04:15PM	Biotech Finds Market Love at Last as Meme Traders, FDA Converge Bloomberg
04:07PM	Biogens Alzheimers Drug Opens Up a New Market. These Stocks Could Benefit if More Approvals Come. Barrons.com
02:27PM	Biogen stock heads for biggest weekly rally in more than 2 decades, UBS analyst targets more gains MarketWatch
01:19PM	A Third Expert Quits FDA Panel Over Approval of Biogen Alzheimers Drug Barrons.com
12:31PM	Three FDA members resign over Biogen's Alzheimer drug approval: RPT Yahoo Finance Video
12:18PM	Dow Jones Slips As These 2 Key Stocks Weigh; Nasdaq Aims For Big Weekly Gain Investor's Business Daily
09:50AM	Bipartisan group agrees on infrastructure bill, FDA member resigns over controversy, two guests test positive on cruise Yahoo Finance Video
08:55AM	Biogen Gains, Vertex Pharmaceuticals Drops, and the Stock Market Keeps Rising Barrons.com
06:45AM	Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments Motley Fool
06:39AM	Biogen Analysts Upgrade Stock Amid Alzheimer's Drug Controversy TheStreet.com
12:58AM	PRESS DIGEST- Wall Street Journal - June 11 Reuters
Jun-10-21 08:00PM	The Alzheimers economy: is the new $56,000-a-year drug worth it? Financial Times
07:59PM	Is Biogen Stock a Buy Right Now? This Is What You Need to Know TipRanks
05:58PM	Medicare copays for new Alzheimers drug could hit $11,500 annually MarketWatch
05:08PM	Column: The FDA's hasty approval of an unproven Alzheimer's drug is bad news for everyone LA Times
04:19PM	Why Biogen, Lilly, and Prothena Stocks Soared This Week Motley Fool
04:06PM	Biogen Announces Investor Day on September 21, 2021 GlobeNewswire
07:30AM	New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogens Commitment to Innovation in SMA Therapy GlobeNewswire
06:43AM	The Zacks Analyst Blog Highlights: Intel, NextEra Energy, PetroChina, Illumina and Biogen Zacks
Jun-09-21 03:53PM	Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More Zacks
11:43AM	Top Research Reports for Intel, NextEra Energy & PetroChina Zacks
04:02AM	Biogen's Japanese Partner on Alzheimer's Drug Set for Gains TheStreet.com
Jun-08-21 07:33PM	Biogen Sinks Despite Raft of Analyst Upgrades Motley Fool
06:28PM	FDA Approval of New Alzheimers Drug May Boost Prospects of Other Treatments The Wall Street Journal
04:05PM	Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use? Investor's Business Daily
04:04PM	For runner with Alzheimer's, new drug offers hope of keeping on track Reuters
03:34PM	The new Alzheimers drug is about $50,000 too expensive Quartz
03:18PM	Senator Takes Aim at Biogen's New Alzheimer's Drug Motley Fool
02:27PM	Biogen expects its $56,000 Alzheimer's drug to be covered by Medicare for 'most' patients MarketWatch
12:27PM	S&P 500 Continues Holding Pattern Ahead of Inflation Data Investing.com
12:14PM	Doctors 'won't come out of the gates prescribing' new Alzheimer's drug: Analyst Yahoo Finance Video
10:31AM	UPDATE 1-Biogen to start shipping Alzheimer's drug in about two weeks Reuters
10:29AM	Biogen (BIIB) Up as FDA Approves Alzheimer'S Drug Aducanumab Zacks
10:15AM	Biotech ETFs Surge on Biogen's Alzheimer Drug Approval Zacks
10:09AM	3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug Zacks
10:02AM	Biogen gets FDA approval for Alzheimer's treatment Yahoo Finance Video
09:36AM	S&P 500 in Sideways Action; Clover Health Rides Meme Wave Higher Investing.com
08:46AM	What to Know About the FDAs Approval of Biogens Alzheimers Drug Barrons.com
08:42AM	Biogen to start shipping Alzheimer's drug in about two weeks Reuters
08:41AM	Biogen Is Charging $56,000 for Its Alzheimers Drug. Why Thats a Problem. Barrons.com
08:24AM	Dow Jones Futures: Tesla China Sales Jump, Marvell Joins New Market Rally Breakouts While Bitcoin Dives Investor's Business Daily
08:20AM	An Outage Hit Major Websites. The Internets Infrastructure Appears Shaky. Barrons.com
07:51AM	Biogens ADUHELM Receives Accelerated Approval from FDA; Shares Soar 38% SmarterAnalyst
07:12AM	Dow Jones Futures: Marvell Set To Join Market Rally Breakouts, Tesla China Sales Jump After Biogen Skyrockets On Alzheimer's Drug Investor's Business Daily
06:43AM	Updating Our Biogen Targets as It Soars on Alzheimer Drug Approval TheStreet.com
06:14AM	Biogen Lifted to Neutral at Bank of America, Baird After FDA Approval TheStreet.com
06:03AM	Could Biogen Be a Millionaire-Maker Stock? Motley Fool
05:52AM	Should You Buy Biogen Stock After Its Stunning FDA Win? Motley Fool
03:28AM	Biogen Soars as Alzheimers Approval Cheers Investors Bloomberg
01:07AM	Nvidia, Biogen and Tesla - 5 Things You Must Know Tuesday TheStreet.com
01:05AM	Biogen Shares Soar to All-Time High On Alzheimers Drug Approval FX Empire
Jun-07-21 08:00PM	Biogens $56,000-a-year Alzheimers drug reignites US debate over costs Financial Times +38.34%
06:16PM	Big Biogen boost on Alzheimer's news could win back biotech investors Reuters
06:12PM	Biogen's New Alzheimer's Drug Will Cost $56,000 Per Year Motley Fool
05:45PM	Biogen's Alzheimer Drug Wins FDA Approval Zacks
05:18PM	6 Million Americans Are Rooting for Monday's Big Stock Market Winner Motley Fool
05:05PM	Dow Jones Futures: Market Rally Mixed, But Biogen Stock Skyrockets On Alzheimer's Drug, 5 Stocks Enter Buy Zones; Marvell Signals Breakout Investor's Business Daily
04:40PM	FDA Approves First New Alzheimers Drug in Nearly Two Decades The Wall Street Journal
04:33PM	Biogens Alzheimers Drug Is a Wall Street Winner, Controversy or Not The Wall Street Journal
04:26PM	Stock Market Today: Small-Cap Stocks Sprint Out of the Blocks Kiplinger
04:22PM	US STOCKS-S&P closes nominally lower as investors wait for a catalyst Reuters
04:15PM	Biotech Shares Soar as Biogen Drug Approval Stokes Optimism Bloomberg
04:13PM	Biogen stock rockets to 6-year high after Alzheimers drug gets FDA OK MarketWatch
04:08PM	Biogen Stock Rockets To Record High On Alzheimer's Drug Approval; 5 Things To Know Investor's Business Daily
03:51PM	Why Eli Lilly Stock Soared Today Motley Fool
02:48PM	EXPLAINER-What does FDA approval of Biogen's Alzheimer's drug mean for patients? Reuters
02:31PM	US STOCKS-Wall Street mixed as buyers step to sidelines Reuters
02:00PM	Why Cassava Sciences Was Up 15% in May Motley Fool
01:51PM	Biogen Stock Jumps on FDA Approval. What Wall Street Is Saying. Barrons.com
01:01PM	Biogen and Eisai launch multiple initiatives to help patients with Alzheimers disease access ADUHELM GlobeNewswire
01:00PM	FDA grants accelerated approval for ADUHELM as the first and only Alzheimers disease treatment to address a defining pathology of the disease GlobeNewswire
12:45PM	Biogen's Alzheimer's Disease Treatment Earns FDA Approval Motley Fool
12:43PM	Biogen Rockets To Record On Watershed Alzheimer's Drug Approval; 5 Things To Know Investor's Business Daily
12:30PM	Why Biogen Stock Is On Fire Today Motley Fool
11:58AM	Biogens Alzheimers Drug Is Approved by the FDA. The Price? $56,000 a Year. Barrons.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sandrock Alfred	Head of Research & Development	Jun 07	Sale	440.00	7,672	3,375,680	10,169	Jun 09 07:05 PM
Guindo Chirfi	Head of Glob Prod Strat & Com	Jun 07	Sale	440.00	3,087	1,358,280	2,919	Jun 09 07:04 PM
Posner Brian S	Director	Jun 04	Sale	274.17	360	98,701	7,400	Jun 07 07:02 PM
Sandrock Alfred	EVP, Research & Development	Feb 12	Option Exercise	0.00	4,454	0	19,715	Feb 17 05:01 PM
Vounatsos Michel	Chief Executive Officer	Feb 12	Option Exercise	0.00	16,289	0	60,194	Feb 17 05:03 PM
Kramer Robin	SVP, Chief Accounting Officer	Feb 12	Option Exercise	0.00	333	0	706	Feb 17 04:59 PM
Guindo Chirfi	EVP Glob. Prod Strat and Comm	Feb 12	Option Exercise	0.00	3,156	0	6,946	Feb 17 04:58 PM
Gregory Ginger	EVP, Human Resources	Feb 12	Option Exercise	0.00	2,923	0	9,288	Feb 17 04:56 PM
Galdes Alphonse	EVP Pharmaceutical Oper & Tech	Feb 12	Option Exercise	0.00	1,573	0	4,765	Feb 17 04:54 PM
ALEXANDER SUSAN H	EVP Chief Legal Off & Corp Sec	Feb 12	Option Exercise	0.00	4,355	0	43,509	Feb 17 04:52 PM
Mantas Jesus B	Director	Feb 09	Buy	267.00	898	239,766	2,943	Feb 10 04:31 PM
Kramer Robin	VP, Chief Accounting Officer	Dec 03	Option Exercise	0.00	74	0	395	Dec 07 09:08 PM
Guindo Chirfi	EVP Glob. Prod Strat and Comm	Dec 01	Option Exercise	0.00	481	0	4,004	Dec 03 05:41 PM
Vounatsos Michel	Chief Executive Officer	Nov 30	Buy	241.31	3,100	748,047	34,810	Dec 01 04:57 PM
Sandrock Alfred	EVP, Research & Development	Nov 04	Sale	350.00	1,500	525,000	13,066	Nov 06 09:39 PM
Gregory Ginger	EVP, Human Resources	Jul 31	Option Exercise	0.00	212	0	4,786	Aug 04 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience